A Phase 3, Open-label Study of JVC-001 in Healthy Japanese Children 5 to 6 Years of Age

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225022

Enrollment

100

Registered

2020-01-20

Start date

2020-01-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prophylaxis of measles, mumps, and rubella

Interventions

investigational material(s) Generic name etc : freeze-dried live attenuated measles, mumps, rubella combined vaccine INN of investigational material : - Therapeutic category code : 631 Vaccines Dosage

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Japanese healthy children of 5 years and older and younger than 6 years - Subjects with history of measles, mumps, and rubella virus vaccination

Exclusion criteria

Exclusion criteria: Subjects with measles, mumps, or rubella infection

Design outcomes

Primary

Measure	Time frame
efficacy - Seroprotection rate of anti-measles virus antibody - Seroprotection rate of anti-rubella virus antibody - Seroprotection rate of anti-mumps virus antibody	—

Secondary

Measure	Time frame
efficacy - Seroconversion rate and GMT of anti-measles virus antibody - Seroconversion rate and GMT of anti-rubella virus antibody - Seroconversion rate, seroresponse rate, and GMT of anti-mumps virus antibody	—

Countries

Japan

Contacts

Public ContactContact for Clinical Trial Information

dsclinicaltrial_jp@daiichisankyo.com

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026